Legg Mason Global Infrastructure ETF
Most Recent
HealthcareWill Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Company & Industry OverviewsComparing Revenue Growth Trends for AMRN and IOVA
In its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which represents a YoY rise of more than 50%.
Company & Industry OverviewsWhat Are Analysts Recommending for AMRN and IOVA in May?
The consensus recommendation for Amarin in May is a “strong buy,” while the consensus recommendation for Iovance Biotherapeutics is a “buy.”
Company & Industry OverviewsMirati Therapeutics Stock Has Delivered Solid Growth in 2018
On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.
Company & Industry OverviewsIovance Biotherapeutics: The News That Drove Up the Stock
On October 12, Iovance Biotherapeutics (IOVA) stock rose 19.66% to $11.93 after the announcement of the price for its public offering.